Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients

Inclusion Criteria: * Between the ages of 1 to 20 (prior to 21st birthday) * End Stage Renal Disease * Necessity of kidney transplant * First kidney transplant received from a living donor * A living kidney donor identified * No known contraindications to therapy with alemtuzumab * Negative pregnancy test before study entry * Willing to use approved methods of contraception for the duration of the study, 6 weeks after discontinuation of MMF, and 12 weeks after discontinuation of sirolimus * Informed consent from participant, parent, or guardian * Current vaccinations, including varicella-zoster (VZV) vaccine, before study enrollment Exclusion Criteria: * Recipient of a deceased donor kidney transplant * Multiorgan transplant * History of prior organ transplantation * Participant sensitized to greater than 0% Panel Reactive Antibody (PRA) within 4 weeks before study enrollment. (If participant receives a blood transfusion status post PRA test, then the PRA must be repeated within 1 week of transplantation) * Participants with human leukocyte antigen (HLA) identical living related donors * History of primary focal segmented glomerulosclerosis * History of other disorders requiring continuous maintenance steroids or calcineurin inhibitors * Active systemic infection at time of transplant * History of malignancy * Infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) * Contraindication to receive tacrolimus, sirolimus, MMF, or mo…